Company Overview: Advanced Cell Technology, Inc. (OTCBB: ACTC) is an emerging biotechnology company applying human embryonic stem (“ES”) cell technology in the field of regenerative medicine with the goal of bringing effective, patient-specific therapies to the bedside. On August 23, 2006, the Company announced technique to generate ES cells without destroying the embryo, a breakthrough in the ethical debate surrounding stem cell research. Recently the Company published positive data for their RPE cells in animal models, and is expecting to file an IND for that application in the 2nd half of 2007 and two more IND’s in 2008. The Company owns or licenses over 300 patents and patent applications in the field, and plans to use its proprietary technology to develop treatments for dermal injuries, macular degeneration, and blood and cardiovascular diseases. One of only two U.S. public companies in the field of regenerative medicine and stem cell technology, Advanced Cell is focused on being the first to commercialize the most profitable applications of regenerative medicine.

Key Market Data:

Exchange: OTCBB: ACTC
52 wk range: $.26-2.95
Shares Outstanding: 41.86 M
Cash Position: $13.12 M (9/30/06)
Market Cap: 40.25 M

Recent Announcements:

• Jan. 13: Advanced Cell Awarded Federal Grant from National Institutes of Health to Accelerate Embryonic Stem Cell Research
• Jan. 10: Advanced Cell Technology CEO Interviewed on CNBC’s "Power Lunch"
• Jan. 5: William M. Caldwell, IV, CEO interviewed by Bloomberg TV to comment on the effect the New Congress will have on stem cell funding
• Dec. 7: Robert Lanza M.D., delivers keynote address at Florida Vision Research Symposium
• Nov. 9: Current Chief Executive Officer William M. Caldwell IV named Chairman of the Board

Human Embryonic Stem Cells –
"This small colony of human embryonic stem cells can become any type of cell found in the human body."

Investment Highlights:

• Revolutionary technique to generate embryonic stem cells that maintains the developmental potential of the embryo and has the potential to shift ethical debate.
• Strong IP protection: owns or licenses over 300 patents and patent applications related to the field of stem cell therapy.
• Large Target Market in the field of Regenerative Medicine: Regenerative Medicine has the potential to treat diseases of the eye, blood disorders, heart disease, neurodegenerative diseases, liver disease, diabetes, and others.
• Led by experienced management team and scientific experts in the field, including Michael D. West, Ph.D., founder of Geron, and Robert Lanza M.D., two of the most published scientists in the stem cell and regenerative medicine spaces.
• Growing legislative support: --CA Prop. 71 provides $3.0 billion in funding over 10 years for stem cell research, with preference given to research that is ineligible for NIH funding.
Target Applications

RPE Cells--For retinal degenerative disease of the eye, including macular degeneration (AMD)
- Large Target Market: Over 10 million cases of AMD in U.S.
- Early animal tests show therapeutic potential
- Targeting GMP cell production in 2006
- IND expected to be filed in the second half of 2007

Hemangioblast Cells--For the treatment of multiple blood and cardiac disorders (vascular disease)
- Large Target Market: Over 20 million cases of heart disease in U.S.
- Published data in animal models show strong therapeutic potential
- Cells isolated in Massachusetts labs
- Completing proof of concept studies with leading institutions in the field.
- IND expected to be filed in 2008

Dermal Cells--For the treatment of dermal damage, including burns, wound repair and surgery
- Wide range of applications with large target markets
- Cells isolated in California labs
- Focusing on proof of concept studies with collaborators and experts in the field
- IND expected to be filed in 2008

Single Cell Biopsy: Revolutionary Embryonic Stem Cell Generation Technique

Management Team:
William M. Caldwell, IV, Chairman & Chief Executive Officer
30-year career in management & finance

Dr. Michael West, President & Chief Scientific Officer
Founder of Geron and Advanced Cell Technology

Dr. Robert Lanza, VP of Research & Scientific Development
25-year career in biomedical and scientific research

Ivan Wolkind, V.P. Finance & Chief Accounting Officer

Jon Atzen, SVP, General Counsel
15-year legal career in corporate and securities law

Contact Information:
Investors: James Carbonara
Media: Bill Douglass
The Investor Relations Group
11 Stone Street, 3rd Floor
New York, NY 10004
212-825-3210

Forward-Looking Statements: This document contains “forward-looking statements” as defined under the federal securities laws. Actual results could vary materially. Factors that could cause actual results to vary materially are described in our filings with the Securities and Exchange Commission. You should pay particular attention to the “risk factors” contained in documents we file from time to time with the Securities and Exchange Commission. The risks identified therein, as well as others not identified by the Company, could cause the Company's actual results to differ materially from those expressed in any forward-looking statements. The Investor Relations Group, Inc. is a paid consultant and may hold a long position in the company.